Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial

In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-11-16
DOI
https://doi.org/10.1182/blood.2026035635
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial

Mattia D’Agostino, Massimo Gentile, Michele Cea, Francesca Fioritoni et al.
Blood
Multiple Myeloma Research and Treatments
article

Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial

Mattia D’Agostino, Massimo Gentile, Michele Cea, Francesca Fioritoni, Stefania Oliva, Sara Aquino, Micol Quaresima, Benedetto Bruno, Delia Rota‐Scalabrini, Pellegrino Musto, Giuseppe Bertuglia, Paolo de Fabritiis, Stelvio Ballanti, Paolo Corradini, Elena Zamagni, Francesca F. Patriarca, Renato Zambello, Sara Bringhen, Francesca Fazio, Angelo Belotti, Nicola Giuliani, Sonia Morè, L. Paris, Francesca Gay, Mario Boccadoro
article en

Abstract

In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643

Blood
University of Parma (IT), University of Udine (IT), University of Padua (IT), University of Milan (IT), Policlinico Umberto I (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Azienda Ospedaliera di Perugia (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), Azienda Ospedaliero Universitaria San Giovanni Battista (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Papa Giovanni XXIII (IT), Ospedali Riuniti di Ancona (IT), Ospedale Annunziata di Cosenza (IT), Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT), St. Eugenio Hospital (IT), Ospedale Policlinico San Martino (IT), Azienda USL di Pescara (IT), Candiolo Cancer Institute (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Genoa (IT)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon